The intestinal epithelium provides a critical interface between lumenal bacteria and the mucosal immune system. Whereas normal commensal flora do not trigger acute inflammation, pathogenic bacteria trigger a potent inflammatory response. Our studies emanate from the hypothesis that the intestinal epithelium is normally hyporesponsive to commensal pathogen-associated molecular patterns (PAMPs) such as LPS. Our data demonstrate that normal human colonic epithelial cells and lamina propria cells express low levels of TLR4 and its co-receptor MD-2. This expression pattern is mirrored by intestinal epithelial cell (IEC) lines. Co-expression of TLR4 and MD-2 is necessary and sufficient for LPS responsiveness in IEC. Moreover, LPS sensing occurs along the basolateral membrane of polarized IEC in culture. Expression of MD-2 is regulated by IFN-γ. Cloning of the MD-2 promoter demonstrates that promoter activity is increased by IFN-γ and blocked by the STAT inhibitor SOCS3. We conclude from our studies that the intestinal epithelium down-regulates expression of TLR4 and MD-2 and is LPS unresponsive. The Th1 cytokine IFN-γ up-regulates expression of MD-2 in a STAT-dependent fashion. The results of our studies have important implications for understanding human inflammatory bowel diseases.
References
1.
Dunne C.Adaptation of bacteria to the intestinal niche: probiotics and gut disorder . Inflamm Bowel Dis2001; 7: 136—145.
2.
Naidu AS, Bidlack WR, Clemens RAProbiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr1999; 39: 13—26.
3.
Sartor RBRole of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther1997 ; 11: 17—23.
4.
Duchmann R., Kaiser I., Hermann E., Mayet W., Ewe K., Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol1995; 102: 448—455.
5.
Nusrat A., Turner JR, Madara JLMolecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol2000; 279: G851—G857.
6.
Kim JM, Eckmann L., Savidge TC, Lowe DC, Witthoft T., Kagnoff MFApoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest1998; 102: 1815—1823.
7.
Hecht G.Innate mechanisms of epithelial host defense: spotlight on intestine. Am J Physiol1999; 277: C351—C358.
8.
Sansonetti PJ , Phalipon A.M cells as ports of entry for enteroinvasive pathogens: mechanisms of interaction, consequences for the disease process . Semin Immunol1999; 11: 193—203.
9.
Rescigno M., Urbano M., Valzasina B. et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol2001; 2: 361—367.
10.
Rutgeerts P. , Goboes K., Peeters M. et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet1991; 338: 771—774.
11.
Janowitz HD , Croen EC, Sachar DBThe role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis1998; 4: 29—39.
12.
Greenbloom SL, Steinhart AH, Greenberg GRCombination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol1998; 12: 53—56.
13.
Gionchetti P., Rizzello F., Venturi A. et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther1999; 13: 713—718.
14.
Macfarlane GT, Macfarlane S.Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl1997; 222: 3—9.
15.
Abreu MT, Vora P., Faure E., Thomas LS, Arnold ET, Arditi M.Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol2001; 167: 1609—1617.
16.
Naik S., Kelly EJ, Meijer L., Pettersson S., Sanderson IRAbsence of Toll-like receptor 4 explains endotoxin hyporesponsiveness in human intestinal epithelium. J Pediatr Gastroenterol Nutr2001; 32: 449—453.
17.
Ades EW, Candal FJ, Swerlick RA et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol1992 ; 99: 683—690.
18.
Abreu MT, Arnold ET, Thomas LS et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem2002; 277: 20431—20437.
19.
Abreu MT, Vora P., Faure E., Thomas LS, Arnold ET, Arditi M.Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol2001; 167: 1609—1616.
20.
Faure E., Equils O., Sieling PA et al. Bacterial lipopolysaccharide activates NF-kappaB through Toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem2000; 275: 11058—11063.
21.
Abreu MT, Palladino AA, Arnold ET, Kwon RS, McRoberts JAModulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells. Gastroenterology2000; 119: 1524—1536.
22.
McIntire FC , Sievert HW, B arlow GH, Finley RA, Lee AYChemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry1967; 6: 2363—2372.
23.
Qureshi N., Takayama K., Sievert TR et al. Novel method for the purification and characterization of lipopolysaccharide from Escherichia coli D31m3. Prog Clin Biol Res1995; 392: 151—160.
24.
Hirschfeld M., Ma Y., Weis JH, Vogel SN, Weis JJRepurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol2000; 165: 618—622.
25.
Zhang FX, Kirschning CJ, Mancinelli R. et al. B acterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem1999; 274: 7611—7614.
26.
Abreu-Martin MT, Chari A., Palladino AA, Craft NA, Sawyers CLMitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol1999; 19: 5143—5154.
27.
Matsusaka T. , Fujikawa K., Nishio Y. et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA1993; 90: 10193—10197.
28.
Shimazu R., Akashi S., Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med1999; 189: 1777—1782.
29.
Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot RP, Jove R.Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol1998; 18: 2545—2552.
30.
Novak U., Marks D., Nicholson SE, Hilton D., Paradiso L.Differential ability of SOCS proteins to regulate IL-6 and CSF-1 induced macrophage differentiation. Growth Factors1999; 16: 305—314.
31.
Abreu MT, Arnold ET, Chow Jyc, Barrett KEPI3'-kinase-dependent pathways oppose Fas-induced apoptosis and limit chloride secretion in human epithelial cells; implications for inflammatory diarrheal state. J Biol Chem2001; 276: 47563—47574.
32.
Abreu-Martin MT, Vidrich A., Lynch DH, Targan SRDivergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen . J Immunol1995; 155: 4147—4154.
33.
Guimbaud R., Bertrand V., Chauvelot-Moachon L. et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol1998; 93: 2397—2404.
Eaves-Pyles T. , Murthy K., Liaudet L. et al. Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J Immunol2001; 166: 1248—1260.
36.
Madara JL, Dharmsathaphorn K.Occluding junction structure-function relationships in a cultured epithelial monolayer. J Cell Biol1985; 101: 2124—2133.
37.
Papadakis KA , Targan SRTumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology2000; 119: 1148—1157.
38.
Plevy SE, Landers CJ, Prehn J. et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol1997; 159: 6276—6282.
39.
Rehli M., Poltorak A., Schwarzfischer L., Krause SW, Andreesen R., Beutler B.PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J Biol Chem2000; 275: 9773—9781.
40.
Faure E., Thomas L., Xu H., Medvedev A., Equils O., Arditi M.Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol2001; 166: 2018—2024.
41.
Schultz M., Sartor RBProbiotics and inflammatory bowel diseases. Am J Gastroenterol2000; 95: S19—S21.
42.
Rath HC, Ikeda JS, Linde HJ, Scholmerich J., Wilson KH, Sartor RBVarying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology1999; 116: 310—319.
French N., Pettersson S.Microbe-host interactions in the alimentary tract: the gateway to understanding inflammatory bowel disease. Gut2000; 47: 162—163.
45.
Cohavy O., Bruckner D., Gordon LK et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun2000; 68: 1542—1548.
46.
Sandborn W. , McLeod R., Jewell D.Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database of Systematic Reviews2000: CD001176.
Gionchetti P., Rizzello F., Venturi A. et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial [see comments]. Gastroenterology2000 ; 119: 305—309.
49.
Rembacken BJ , Snelling AM, Hawkey PM, Chalmers DM, Axon ATNon-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial [see comments] . Lancet1999; 354: 635—639.
50.
Prantera C. , Zannoni F., Scribano ML et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol1996 ; 91: 328—332.
51.
Hulten K., Almashhrawi A., El-Zaatari FA, Graham DYAntibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria. Dig Dis Sci2000; 45: 445—456.
52.
Ogura Y., Bonen DK, Inohara N. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature2001; 411: 603—606.
53.
Hugot JP, Chamaillard M., Zouali H. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature2001; 411: 599—603.
54.
Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology2002; 123: 679—688.
55.
Cario E., Podolsky DKDifferential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun2000; 68: 7010—7017.
56.
Swidsinski A., Ladhoff A., Pernthaler A. et al. Mucosal flora in inflammatory bowel disease. Gastroenterology2002; 122: 44—54.
57.
Elewaut D., DiDonato JA, Kim JM, Truong F., Eckmann L., Kagnoff MFNF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol1999; 163: 1457—1466.
58.
Jung HC, Eckmann L., Yang SK et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest1995; 95: 55—65.
59.
Eckmann L., Kagnoff MF, Fierer J.Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect Immun1993; 61: 4569—4574.
60.
Savkovic SD , Koutsouris A., Hecht G.Activation of NF-kappaB in intestinal epithelial cells by enteropathogenic Escherichia coli. Am J Physiol1997; 273: C1160—C1167.
